Search

Your search keyword '"Teti, E."' showing total 171 results

Search Constraints

Start Over You searched for: Author "Teti, E." Remove constraint Author: "Teti, E."
171 results on '"Teti, E."'

Search Results

1. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

2. Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions

3. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

4. Changing HCV patient profiles: insights from a large multinational real-world sofosbuvir/velpatasvir (SOF/VEL) dataset

6. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

7. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

8. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

9. Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial

10. An in-depth characterization of VOCs circulation by using NGS analysis of the Spike protein

13. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

14. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

15. Whole-brain white matter network reorganization in HIV

16. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

17. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

18. Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis

19. Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy

20. Trend of estimated glomerular filtration rate during ombistasvir/paritaprevir/ritonavir plus dasabuvir± ribavirin in HIV/HCV co-infected patients

21. Genetic Determinants in a Critical Domain of NS5A Correlate with Hepatocellular Carcinoma in Cirrhotic Patients Infected with HCV Genotype 1b

22. Analysis of resistance and phylogenetic clusters in HCV-2c infected patients within the Italian network Vironet C

23. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

24. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies

27. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

28. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

29. HCV NS3 sequencing as a reliable and clinically useful tool for the assessment of genotype and resistance mutations for clinical samples with different HCV-RNA levels

30. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

31. Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance

32. Corrigendum to 'Brain and cognitive functions in two groups of naïve HIV patients selected for a different plan of antiretroviral therapy: A qEEG study' [Clin. Neurophysiol. 127 (2016) 3455–3469]((S1388245716305089)(10.1016/j.clinph.2016.09.001))

33. Corrigendum to 'Abnormal cortical sources of resting state electroencephalographic rhythms in single treatment-naïve HIV individuals: A statistical z-score index' [Clin. Neurophysiol. 127 (2016) 1803–1812] (S138824571501559X) (10.1016/j.clinph.2015.12.007))

34. On treatment HCV-RNA evaluation in real-life: Still a role in the era of direct acting antiviral agents?

35. Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

36. Real world adherence to Direct-Acting Antivirals in a cohort of drug users in Rome, Italy

37. Comparison of resistance profiles among DAA-naive and DAA-experienced patients infected with HCV non-1 genotype in Italy

38. Characterization of resistance profiles in HCV 2-3-4 DAA-naïve and DAA-experienced infected patients in Italy

39. Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program

40. Optimal efficacy of interferon-free HCV retreatment after protease inhibitor failure in real life

41. HCV resistance test guided retreatments after protease inhibitors failures can induce maximal efficacy rate in real-life

42. Natural HCV resistance is common in Italy and differently associated to genotypes

43. Prevalence and characteristics of resistance associated substitutions in DAA-naive and DAA-failed HCV-3 patients in Italy

44. Clinical relevance of accurate HCV genotype and subtype assignment by NS3/NS5A/NS5B direct sequencing in the era of new direct acting antiviral agents

45. Biphasic Kinetics of HCV-RNA Decay is Accompanied by an even Faster Aminotransferases Normalization in All-Daa Treated Cirrhotic Patients: A Different Scenario from Interferon-Based Therapies

46. In the ERA of New Direct Acting Antiviral Agents HCV Sequencing Allows the Most Accurate Subtype and Genotype Assignment

47. Dasabuvir and Ombitasvir/Paritaprevir/Ritonavir with or without Ribavirin in Patients with HIV-HCV Coinfection: Real Life Interim Analysis of an Italian Multicentre Compassionate Use Program

48. Antiretroviral therapy effects on sources of cortical rhythms in HIV subjects: responders vs. mild responders

49. FRI-379 - Lack of reduction of serum alphafetoprotein during treatment with direct antiviral agents predicts hepatocellular carcinoma development in a large cohort of patients with HCV-related cirrhosis

Catalog

Books, media, physical & digital resources